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http://www.biomedcentral.com/2046-1682/7/5RESEARCH ARTICLE Open AccessInsights into the mechanism of C5aR inhibition by
PMX53 via implicit solvent molecular dynamics
simulations and docking
Phanourios Tamamis1, Chris A Kieslich2, Gregory V Nikiforovich3, Trent M Woodruff4, Dimitrios Morikis2* and
Georgios Archontis1*Abstract
Background: The complement protein C5a acts by primarily binding and activating the G-protein coupled C5a
receptor C5aR (CD88), and is implicated in many inflammatory diseases. The cyclic hexapeptide PMX53 (sequence
Ace-Phe-[Orn-Pro-dCha-Trp-Arg]) is a full C5aR antagonist of nanomolar potency, and is widely used to study C5aR
function in disease.
Results: We construct for the first time molecular models for the C5aR:PMX53 complex without the a priori use
of experimental constraints, via a computational framework of molecular dynamics (MD) simulations, docking,
conformational clustering and free energy filtering. The models agree with experimental data, and are used to
propose important intermolecular interactions contributing to binding, and to develop a hypothesis for the
mechanism of PMX53 antagonism.
Conclusion: This work forms the basis for the design of improved C5aR antagonists, as well as for atomic-detail
mechanistic studies of complement activation and function. Our computational framework can be widely used
to develop GPCR-ligand structural models in membrane environments, peptidomimetics and other chemical
compounds with potential clinical use.
Keywords: Class A GPCR, C5aR, C5a, Complement system, Molecular dynamics, Docking, Implicit solvent,
Membrane proteinBackground
C5aR is the membrane-bound receptor for the comple-
ment system protein C5a and the target of inhibition
against inflammatory diseases. Here, we present the
development of a structural model for the complex of
membrane-embedded C5aR and its antagonist peptide
PMX53. We accomplish this by an innovative and com-
prehensive computational framework that combines con-
formational sampling for both receptor and ligand with
docking, and evaluates a large number (~300,000) of
docked conformations by structural and free energy cri-
teria. Even though we do not impose any experimental* Correspondence: dmorikis@ucr.edu; archonti@ucy.ac.cy
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unless otherwise stated.restraints, the resulting structural models are consistent
with available experimental data.
The complement system is a major and essential com-
ponent of the innate immune response. It can be acti-
vated following infection or injury through four distinct
pathways, which lead to opsonisation of pathogens, cell
lysis, and the production of potent pro-inflammatory
peptides. The complement protein C5a is generated fol-
lowing cleavage of the 5th component of complement
(C5), and is one of the most potent inflammatory media-
tors in humans [1]. Given its potent inflammatory activ-
ity, prolonged or inappropriate activation of complement
can generate unwanted C5a, which is implicated in many
inflammatory diseases [2,3].
C5a induces the majority of its known effects primarily
through a G-protein coupled receptor, termed C5aR. It
can also bind to a second receptor called C5L2, howeveral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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unclear and controversial functions [4]. The C-terminal
ten residues of C5a have been shown to be critical for
C5aR activation, and can induce full activation (efficacy)
of C5aR, albeit at lower potencies than intact C5a. This
C-terminus is proposed to act at the second extracellular
loop of C5aR [5].
Given the proposed involvement of C5a in classical in-
flammatory diseases such as rheumatoid arthritis, [6] and
a widening of the pathogenic roles of C5a to traditionally,
non-inflammatory diseases such as cancer [7], and brain
diseases [8], there has been a burgeoning interest in devel-
oping inhibitors of C5a for clinical use [9]. One such
method has been to block C5a-C5aR interaction through
the development of selective C5aR antagonists. In 1999
and 2000, a series of cyclic peptide full antagonists were
described which were designed around the C-terminal res-
idues of C5a [10,11]. One of these compounds, termed
3D53 (later named PMX53), has been the most exten-
sively studied, and is widely used to study C5aR function
in disease [3]. It is a cyclic hexapeptide (structure: Ace-
Phe-[Orn-Pro-dCha-Trp-Arg]), which has low nanomolar
potency, and efficacy in a wide range of species [12], mak-
ing it an ideal research tool [3]. One potential drawback
for the clinical use of this compound, however, is its pep-
tidic nature and low oral bioavailability [13], which has
limited its commercial development [9].
The recent determination of several GPCR crystal struc-
tures has contributed significantly to our understanding of
GPCR structural organization, ligand specificity, and acti-
vation [14-19]. MD simulations have provided consider-
able insight on the conformations of inactive states and
the mechanism of receptor activation (Ref. [20] and refer-
ences therein). Nevertheless, the generation of reliable
structural models for GPCR proteins of unknown struc-
ture and for their ligand complexes remains a challenging
task [21].
In the present study we develop molecular models of
PMX53 bound to C5aR in a model membrane. Our goal
is to use the resulting models to develop peptidomimetics
[22] and chemical compounds, which may overcome
some of the clinical hurdles that were encountered with
PMX53 [3]. We start from a well-tested earlier structural
model for free C5aR [23-27] and an NMR structure for
PMX53 [28], and generate a large number of representa-
tive conformations for free C5aR and the PMX53 ligand
by multi-ns MD simulations. Docking of the obtained
conformations yields a large number of structural models
for the complex (~300,000 structures); subsequent filter-
ing by structural and energetic criteria identifies a man-
ageable number of candidate complexes, which are
further tested by extensive MD simulations and free
energy calculations. In contrast to previous computational
studies of the C5aR complexes with C5 and PMX53, werepresent membrane effects on the protein and ligand in-
teractions at the MD simulation and assessment stage via
high-quality implicit-membrane models [21,29-31]. Such
models offer a promising alternative to explicit-membrane
treatments, which are more accurate but are impractical
for structure-prediction calculations [32,33]. Furthermore,
the implicit-membrane representation enables the rapid
determination of binding free energies for several hundred
thousand candidate structures. Even though no experi-
mental information has been incorporated a priori in the
docking, the most promising complexes are consistent
with available experimental data, reflecting the accuracy
and potential of the employed methodology.
The obtained models for the C5aR:PMX53 complex
can serve as the basis for knowledge-based discovery of
C5aR antagonists with improved properties compared to
PMX53, as well as for basic mechanistic studies of com-
plement activation and function at molecular detail and
atomic resolution. Furthermore, the described combin-
ation of implicit-membrane MD simulations, docking and
free energy calculations is a promising framework for
the generation and assessment of structural models for
GPCR-ligand complexes.
Methods
Description of simulation systems
C5aR receptor
The human GPCR receptor C5aR consists of 350 amino
acids, and has the typical GPCR topology, with an extra-
cellular N-terminal fragment, seven trans-membrane
(TM) helices interconnected by extracellular (EC) and
intracellular (IC) loops, and an intracellular C-terminal
fragment [26]. Nikiforovich et al. has constructed struc-
tural models for free C5aR [24] as well as its complex
with C5a [25,26]. In the MD simulations we use as a
starting point for C5aR the structural model of Nikiforo-
vich [24-26]. The seven transmembrane helices in the
Nikiforovich model are defined as: 38–63 (H1), 71–98
(H2), 107–138 (H3), 150–172 (H4), 199–224 (H5), 236–
267 (H6), and 281–300 (H7); similarly, the three extra-
cellular loops are defined as 99–106 (EC1), 173–198
(EC2), and 268–280 (EC3) [26]. The simulation system
omits the first seven amino acids, which do not contrib-
ute to C5a binding and are not expected to affect bind-
ing of PMX53. It also omits the intracellular C-terminal
region 307–350, which is very remote from the insertion
point of the C5a C-terminal end, and the putative ligand
binding site.
PMX53 ligand
The hexapeptide PMX53 (Figure 1) has the sequence Ace-
Phe-[Orn-Pro-dCha-Trp-Arg]; Ace denotes the blocking
group CH3-CO at the N-terminal end, Orn ornithine, dCha
d-cyclohexyl-alanine, and the brackets denote cyclization of
A B C
Phe1 Pro3
dCha4
Trp5
Arg6
Ace
Phe1
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dCha4
Trp5
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Phe1
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Orn2 Orn2 Orn2
Figure 1 Structure of the cyclic hexapeptide ligand PMX53, with amino acid sequence Ace-Phe-[Orn-Pro-dCha-Trp-Arg]. Panel A:
two-dimensional Chemical structure PMX53. The N-terminal end is blocked by the group CH3-CO (Ace); Orn denotes ornithine and dCha
d-cyclohexyl-alanine. The brackets denote cyclization via a covalent bond between the Orn side-chain and the Arg6 carbonyl group. Panel B:
three-dimensional representation of the first conformer of the NMR ensemble of structures of PMX53. Atoms are colored according to element
type. Panel C: three-dimensional representation of the ensemble of the NMR structures of PMX53. The color of residues transitions from blue to
red between the N- and C- termini. Hydrogens are omitted for clarity.
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chain and the Arg6 carbonyl group. Figure 1A shows
the chemical structure of PMX53, and Figure 1B,C shows
three-dimensional representations of the NMR structure
of PMX53 [28].
Construction of structural models for the C5aR:PMX53
complex
In order to achieve a systematic construction and evalu-
ation of plausible structural models for the complex, we
employed a range of methods, including MD simulations,
docking, energy minimizations, and binding-affinity calcu-
lations. Our computational framework consisted of the
following steps: (A) generation of a large collection of rep-
resentative PMX53 and C5aR structures via long MD sim-
ulations of the isolated ligand and receptor; (B) clustering
of the simulation trajectories and determination of high-
probability conformations; (C) generation of a large num-
ber of potential structural models for the complex,
via docking of conformations from the most populated
PMX53 and C5aR clusters; (D) filtering of the models with
structural and energetic criteria; (E) assessment of the most
promising models by MD simulations and binding free en-
ergy calculations. Each step is detailed below.
Generation of PMX53 conformations
Competition binding studies with linear and cyclic pep-
tide antagonists suggest that the binding site of PMX53
is in the transmembrane region of C5aR, near or at the
location of the binding site of the C5a C-terminal end
[5]. NMR experiments [28] have shown that the domin-
ant conformation of free PMX53 in deuterated DMSO
(DMSO-d6) has residues 1–2 in a random-coil state, and
segment 3–6 in a type-II β-turn. PMX53 may assume a
different conformation in the complex with C5aR, due
to the influence of the surrounding C5aR receptor andthe embedding membrane. Hence, it is important to gen-
erate alternative structural models of PMX53, which are
likely to be stabilized by the less polar environment of
the binding site. As an approximation, we generated such
conformations by MD simulations of free PMX53 in a
membrane environment, represented by the implicit-
membrane molecular-volume Generalized Born (GBMV)
model [31]. Standard amino acids were described by
the CHARMM all-atom topology and energy function
[34], using the CMAP correction for all L-amino
acids [35]. Topology and parameters for non-standard
groups (ornixthine, cyclohexylalanine and the Orn2-Arg6
cyclization segment of PMX53) were derived, respect-
ively, from CHARMM22 definitions for lysine, alanine/
cyclohexane and the peptide group.
To represent conditions of variable polarity, we con-
ducted four simulations, in which we restrained the
PMX53 center of mass at 0 Å, 10 Å, 15 Å and 20 Å, re-
spectively, from the membrane center. The total simula-
tion length was 180 ns (45 ns per position). We also
conducted an additional 15-ns run in aqueous solution,
represented by the corresponding aqueous GBMV model
[30]. All simulations were conducted with the CHARMM
program, version c35b3 [36].
Classification of PMX53 conformations
The dominant simulation conformation of the PMX53
mainchain was in agreement with the NMR structure
[28], with residues 1–2 in random coil and segment 3–6
in a type-II β-turn. We partitioned the conformations
into groups, based on the following nine side-chain dihe-
dral angles: (i) 1N-1Cα-1Cβ-1Cγ, (ii) 1Cα-1Cβ-1Cγ-1Cδ1,
(iii) 4Ν-4Cα-4Cβ-4Cγ, (iv) 4Cα-4Cβ-4Cγ-4Cδ1, (v) 5Ν-
5Cα-5Cβ-5Cγ, (vi) 5Cα -5Cβ-5Cγ-5Cδ1, (vii) 6Ν-6Cα-6Cβ-
6Cγ, (viii) 6Cα-6Cβ-6Cγ-6Cδ, (ix) 6Cβ-6Cγ-6Cδ-6Nε. We
employed the clustering algorithm of the CHARMM
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imum error” radius (reflecting the maximum difference
among the centers of distinct clusters) of 10°. We ob-
tained a total of 775 clusters, with 51 clusters containing
ca. 30% of the conformations. We employed represen-
tative structures from all 51 clusters in the docking
calculations. The clustering focused on side-chain di-
hedral angles as the side-chains are significantly more
flexible than the backbone. For the 51 clusters, the average
root-mean-square difference (RMSD) of the backbone/
side-chain heavy atoms with regard to the average
structure of the 51 clusters is equal to 0.54 ± 0.15 Å/
2.46 ± 0.52 Å. A significantly higher mobility of the
side-chains compared to the backbone is also present
in the 10 NMR-derived structures (see Figure 1C), ac-
cording to which the average RMSD of the backbone/
side-chain heavy atoms with regard to the average NMR
structure of the 10 conformations is equal to 0.23 ±
0.07 Å/1.85 ± 0.22 Å [28].
Generation of C5aR conformations
The initial C5aR conformation was taken from the Niki-
forovich model for the C5aR:C5a complex [25]. Details
on the construction of the structural models for C5aR
and the C5aR:C5a complex can be found in previous
work [25,39].
Starting from this structure, we generated conforma-
tions of C5aR via MD simulations with the implicit-
membrane switching-function generalized Born (GBSW)
module [29]. Two parameters of this model are the total
thickness of the low-dielectric membrane slab (Tmemb)
and the half-length (lmsw) of the membrane/water inter-
face buffer region. Based on UNIPROT [40] definitions,
we estimated the total thickness of the intra-membrane
C5aR helical region at ~ 35.5 Å. At the same time, the
OPM database [41] yields a hydrophobic thickness of
32.2 ± 1.2 Å for rhodopsin (PDB code 1GZM), the pro-
tein on which the C5aR model is based. We combined
the OPM and UNIPROT predictions, by setting Tmemb
to 36 Å and lmsw to 2.5 Å. With these values, the com-
bination Tmemb – 2* lmsw is 31 Å, i.e. corresponds to the
lower bound of the OPM estimate. Test simulations
indicated a stable behavior (RMSD of ~3.0 Å from
the initial conformation), whereas somewhat different
Tmemb values resulted in larger RMSD from the initial
conformation (~3.5 Å). A similar membrane thickness
(35 Å) and half-length (2.5 Å) were used in recent
structural modeling of class A GPCRs, which employed
the same implicit-membrane model [21]. The surface
tension coefficient (γ) was set to 0.04 kcal/(mol Å2);
other parameters were set to default values of the GBSW
model [21].
To enlarge the ensemble of generated C5aR conforma-
tions, we conducted simulations with four protocols: Inprotocol (i) we removed the C5a ligand and simulated
the C5aR protein at an elevated temperature (400 K),
with harmonic restraints on the heavy backbone atoms
of the entire protein, and the side-chains unrestrained.
In this way, the C5aR binding pocket retained a simi-
lar volume as in the C5aR:C5a complex (Nikiforovich
model) [25], while the simulation eliminated any bias in
the initial side-chain conformations, which might arise
due to interactions with the C5a ligand. In protocols ii-iii
we simulated the complex between C5aR and the C5a
fragment 60–74, which binds at the intra-membrane
C5aR region. The C5a fragment was either restrained
near its initial shape via the bestfit option of CHARMM
(protocol ii), or was left unrestrained (protocol iii). Fi-
nally, in protocol iv we simulated the entire C5aR:C5a
complex without restraints. The simulation temperature
of protocols ii-iv was 300 K. Prior to each production
run, we subjected each system to energy-minimization,
heating, and 1.6-ns equilibration. The length of the pro-
duction run was 11 ns for protocol iii, and 5.5 ns for all
other protocols.
Standard amino acids were described by the CHARMM
all-atom topology and energy function [34] including a
CMAP correction of the backbone torsional angle energet-
ics [35]. Α 16-Å cutoff distance was used for non-bonded
interactions. Τhe lengths of covalent bonds containing
hydrogen atoms were constrained by the SHAKE algo-
rithm [42], and the equations of motion were solved with
an integration time step of 2.0 fs. The system was in con-
tact with a Langevin heat bath at 300 K; a friction coeffi-
cient of 5 ps−1 was used for heavy atoms.
Classification of C5aR conformations
We characterized the C5aR conformations by the shape
of their intra-membrane binding pocket, since structural
differences in other protein regions should not be as
relevant to PMX53 binding. We described the shape of
the binding pocket by a novel methodology, which filled
the binding cavity (after removal of C5a) with particles
having the approximate diameter of a water molecule
and taken from a water box; these particles created a
grid of points, with an inter-point spacing equal to the
water diameter. The underlying premise was that by en-
suring that the particles were always in the same pos-
ition relative to C5aR, it would be possible to identify
the cavity regions that were changing structurally, by
simply keeping track of which particles fit in the cavity.
To create an ensemble of cavity shapes, we first super-
imposed each MD snapshot onto the initial structure
(the Nikiforovich model), based on the Cα-atoms of the
C5aR trans-membrane regions; we then overlayed a
50 Å × 50 Å × 60 Å explicit water box on each snapshot,
and deleted all water molecules whose oxygen atom was
within 2.4 Å of any C5aR heavy atom. Even though C5a
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shapes, water molecules within 4 Å of the coordinates of
the 15 C-terminal residues (60–74) of C5a were used to
define the top of the cavity; water molecules further than
4 Å from these residues were removed.
We created lists identifying the remaining molecules,
and used them to generate binary water fingerprints
with length equal to the number of unique water mole-
cules found in the cavities of the MD snapshots. A value
of 1 (0) was associated with present (absent) water mole-
cules. We quantified the similarity between two water
fingerprints A and B via distance matrices based on the
Jaccard binary distance measure [43].
JAB ¼ C10 þ C01C10 þ C01 þ C11 ð1Þ
In Eq. (1), C11 is the number of common water mole-
cules in both fingerprints (cavities), and C10, C01 are, re-
spectively, the numbers of water molecules only in
fingerprint A or B. The Jaccard distance varies from 0
(fingerprints with the same water molecules) to 1 (no
water molecules in common). We then used hierarchical
clustering [44] to classify the MD snapshots into fam-
ilies, based on water fingerprint similarity, and visualized
the clustering via dendrogram trees. The dendrogram
trees were cut at an arbitrary binary similarity value of
0.3, to keep the number of selected structures manage-
able. With this value, two structures not in the same
cluster differed by more than 50 water molecules. From
each cluster, we selected as most representative the cav-
ity structure with the largest volume (largest number of
present water molecules). Ultimately, we chose 150 –
250 structures from each protocoll (a total of 785 struc-
tures) for the docking studies. These calculations were
performed with scripts written in the R statistical lan-
guage [45] using the Bio3D [46] library. The above
methodology was not employed to the high-temperature
simulation (protocol i), which was restrained to maintain
the volume of the binding cavity; from that trajectory,
we simply extracted structures at intervals of 40 ps.
Docking
Using representative C5aR and PMX53 snapshots from
the structural classification described above, we generated
possible structures of the C5aR:PMX53 complex with the
program DOCK6 [47]. For each C5aR snapshot, we cre-
ated the corresponding molecular surface via DMS [48],
and represented potential binding sites by spheres via the
SPHGEN utility. SPHGEN identifies spheres tangent to
the molecular surface, and performs clustering to elimin-
ate redundant spheres, which represent surface cavities
and serve as potential locations of atoms during ligand
orientation. For each C5aR snapshot combination, we onlyretained spheres within 7 Å of the coordinates for the 15
C-terminal residues of C5a. For protocols ii-iv, the coordi-
nates for C5a were taken from the specific snapshot; for
the elevated temperature run, the C5a coordinates were
taken from the Nikiforovich model. A receptor-ligand
clash was defined as >50% atom-atom overlap of two
atomic radii; we excluded docking poses with more than
five such clashes. All orientations passing this filter were
saved as input for the CHARMM-based scoring proced-
ure, since the docking program was not used to rank the
C5aR:PMX53 poses, due to the complexities of GPCR
docking.
Altogether, 51 PMX53 conformations, corresponding
to the most populated 51 clusters from the PMX53 tra-
jectory analysis, were docked to the representative struc-
tures from each of the four C5aR MD simulations,
resulting in 306,497 structural models for the complex.
A rigid docking procedure was used; nevertheless, the
use of flexible templates of the ligand and the receptor
incorporate flexibility in the docking.
Filtering of docked structures
We subjected all 306,497 docking conformations to
100 energy steepest-descent minimization steps in a
uniform dielectric medium (ε = 4), followed by 50 steepest-
descent minimization steps in the GBSW implicit-
membrane environment. At the end of minimization
we filtered the conformations by a combination of energy-
based and structure-based criteria. A flowchart is pre-
sented in Figure 2.
The energy-based criterion was applied in two steps:
First, we computed the binding free energies of all
306,497 conformations (at the end of minimization) in
the Molecular Mechanics Generalized Born Surface Area
Approximation (MM-GBSA) [49-51], via the following
equation
ΔG ¼ GPL−GP−GL ð2Þ
In Eq. (2), GX is the total free energy of molecule X
(complex PL, free protein P, or free ligand L). The pro-
tein and ligand conformations were assumed identical
in the complex and free molecules. With this assump-
tion, any bonded-energy contributions to ΔG cancel in
Eq. (2). Even though this assumption is not strictly accur-
ate, it is probably sufficient for the identification and
rejection of conformations with weak association free
energies. Protein, ligand and complex entropic contribu-
tions are ignored; they are expected to approximately
cancel when comparing relative affinities of different
binding modes. The solvation components of the com-
plex and free protein free energies were computed in the
inhomogeneous membrane/water environment; the solv-
ation component of the unbound ligand free energy was
Figure 2 Flowchart of the computational framework used to generate and assess structural models of the C5aR:PMX53 complex.
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cit GBSW model) [29]. We thus identified 4676 struc-
tures (resulting from the minimization of the 306,497
docking conformations), whose binding free energies were
within 27 kcal/mol of the binding free energy minimum
(−67 kcal/mol).
In the second filtering step with the energy-based
criterion, we calculated the binding free energies of these
4676 structures in the Molecular Mechanics Poisson-
Boltzmann Surface Area Approximation (MM-PBSA)
[49]. In these calculations, we inserted the complex and
protein in a membrane slab with a thickness of 31 Å
and a dielectric constant of 1, surrounded by water with
a dielectric of 80. The protein dielectric constant was
set to 2. The free ligand was placed in pure water. The
MM-PBSA calculations were performed with the Poisson-
Boltzmann solver of the CHARMM program (PBEQ
module). We used 150 grid points in each direction and a
grid-spacing of 0.5 Å. The MM-PBSA calculation yielded
a more expanded free energy range (between −90 kcal/
mol and −20 kcal/mol), and changed the relative affinity
for some structures. The correlation between MM-GBSA
and MM-PBSA was analyzed via a linear least squares fit;
the slope and the standard error, respectively, were equal
to 1.03 and 0.03.
In the next step, we used a structure-based criterion
in conjunction with the MM-PBSA binding free ener-
gies, to identify structurally distinct, high-affinity binding
modes. Clustering analysis of the PMX53 mainchain coor-
dinates (N, CA and C atoms) with a 5-Å clustering radius
identified 35 clusters, each reflecting a distinct ligand-
binding mode. The analysis was performed with the
program WORDOM [52]. From each cluster we extractedthe conformation of lowest MM-PBSA binding free en-
ergy, and used it as a starting point in MD simulations.
Evaluation of structural models for the C5aR:PMX53
complex by MD simulations
Prior to the MD runs, we relaxed each structure via
1000 steps of steepest-descent energy minimization.
Subsequently, we heated the complexes to a temperature
of 300 K via four 100-ps runs with respective tempera-
tures of 75 K, 150 K, 225 K and 300 K; during the heat-
ing stage we restrained all heavy backbone atoms to
their initial positions by a harmonic force with strength
of 5 kcal/mol/Å2. We then conducted three 400-ps
equilibration runs at 300 K, in which we gradually re-
duced the harmonic-restraint force constant to 1 kcal/
mol/Å2 for intra-membrane residues, and to zero for
residues in extra-cellular (EC) and intra-cellular (IC)
loops. In the subsequent production runs, we removed
all protein and ligand restraints. Parameters and simula-
tion details were the same as for the free ligand and
C5aR simulations, described above. The duration of each
production run was 7 ns, with only the last 4 ns employed
in the analysis.
In order to assess the stabilities of the simulated com-
plexes, we computed the corresponding MM-PBSA as-
sociation free energies. For each run, the results were
averaged over 700 snapshots extracted at 10-ps intervals.
The best complex had a free energy of −175 kcal/mol.
Seven complexes within 20 kcal/mol of the lowest value
(−175 kcal/mol) of less than −155 kcal/mol (20 kcal/mol
greater than the average of the most promising complex)
were simulated for an additional 13 ns (a total of 20 ns);
the last 17 ns were employed in the analysis.
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We analyzed the intermolecular interaction free energies
between PMX53 and C5aR residue pairs of the final
simulation using the following equation:
ΔGinteRR0 ¼
X
i∈R
X
j∈R0
ECoulij þ GGBij
 
︸ΔGpolarRR0
þ
X
i∈R
X
j∈R0
EvdWij þ σ
X
i∈R;R0
ΔSi
︸ΔGnon polarRR0
ð3Þ
The first and second group of terms on the right-hand
side of Eq. (3) describe, respectively, polar and non-polar
interactions between a C5aR residue R and a PMX53
residue R’. The polar component contains a Coulombic
energy term, and a free energy GB contribution, model-
ing the interaction between residue R and the solvent
polarization potential induced by R’. Similarly, the non-
polar component contains a van der Waals interaction
between R, R’ and a surface free energy term, expressing
cavity contributions and nonpolar interactions with the
surrounding solvent.
The non-polar and polar solvation terms were calculated
using the implicit membrane GBSW. The generalized-
Born energies and the atomic accessible-surface areas (ΔSi)
entering in Eq. (3) depend on the location of R and R’ in
the complex. To compute the polar (GB) interaction free
energy term for a particular residue pair (R, R’) in Eq. (3),
we set to zero the charges of atoms not in residues R and
R’. The surface term contains the difference in solvent ac-
cessible surface areas of residues R and R’ in the complex
and unbound states; the interaction free energy non-polar
term represents the creation of a cavity in its surrounding
medium (membrane/water) to accommodate biomolecules
and switching-on dispersion interactions between biomole-
cules and the surrounding medium while all atomic
charges are set to zero [51]. A similar methodology for the
analysis of interacting residues has been used for the eluci-
dation of species-specificity of complement protein C3
[53] and the design of transgenic (mouse/human) C3 with
putative affinity for compstatin [54].
Results and Discussion
Earlier models of free C5aR, and the complex of C5aR
with its natural activator, peptide C5a
The C5aR protein has the typical GPCR topology, with an
extracellular N-terminal fragment, seven trans-membrane
(TM) helices interconnected by extracellular (EC) and
intracellular (IC) loops, and an intracellular C-terminal
fragment [55]. Nikiforovich et al. has constructed struc-
tural models for free C5aR [24], as well as its complex
with C5a [25,26]. The structure of the C5aR TM re-
gion in these models was based on the corresponding
TM region of dark-adapted rhodopsin, and the loopswere constructed with a de novo structure prediction
method [23]. The model has been used to interpret ex-
perimental results on C5a binding to C5aR [25], and to
model the conformational changes occurring during re-
ceptor activation in the TM region [56] and EC loops [27]
of C5aR. The loop prediction method was also applied
with success to construct structural models of extracellu-
lar loops for other GPCR receptors [57].
Numerous systematic experimental studies have led to
a two-site model of C5aR activation (see [2,3] and refer-
ences therein). The primary affinity site involves contacts
between acidic residues in the N-terminal end of C5aR
and basic residues in the core of C5a; interactions in this
site contribute to binding strength, but not to C5aR acti-
vation. The second site is formed by residues in the TM
domain and the EC loops and interacts with the C5a ter-
minal fragment 60–74. This site contributes to the acti-
vation of C5aR by C5a and other peptide agonists.
Experiments with agonist and antagonist peptide mimics
and receptors mutated at possible interaction sites have
provided information on the ligand binding site of C5aR.
Competition-binding experiments suggested that PMX53
binds at or near the same TM location as the C-terminal
moiety of C5a [5]. The substitution Ile116Ala correlated
with the emergence of weak agonist activity in a PMX53
derivative with a bulkier side-chain (benzothiazolalanine)
at position 5 [5], and converted a linear peptide mimic
from antagonist to agonist [58]. These results suggested
that residue 5 of PMX53 (and related peptides) binds in
the vicinity of Ile116. The C5aR substitution Asp282Ala
(in the EC3 loop) caused a 10-fold reduction in PMX53
affinity, suggesting the formation of an electrostatic inter-
action between Arg6 of PMX53 and Asp282. The substi-
tution Arg175Asp converted PMX53 to a weak agonist,
indicating that Arg175 might play a role in the discrimin-
ation between agonists and antagonists; additional experi-
ments suggested a possible interaction between Arg175
and the C-terminal carboxylate of hexapeptide ligands [5].
Mutations Arg206Ala and Glu199Lys also affected the
receptor activation by hexapeptide ligands; modeling in
[5] argued that a possible interaction Arg206-Glu199 may
stabilize the position of helix H5, and disruption of this
interaction may contribute to activation.
Taking into account these experimental results,
Higginbottom et al. constructed two models for the
PMX53:C5aR complex [5]. The C5aR conformation was
based on homology with dark-adapted rhodopsin. Loop
EC2 was kept in a “closed” position (near the membrane),
via a Cys109-Cys188 disulfide bond. Various docking con-
formations of PMX53 inside the C5aR binding pocket
were tried, under the condition that they satisfied two
ligand-receptor interactions: (i) The center of the Trp5 in-
dole ring was restrained within a distance of 5 Å from the
Cα atom of Ile116, and (ii) the side-chain of Arg6 formed
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ing model, the PMX53 Phe1 side-chain was positioned be-
tween helices 6 and 7, in the vicinity of residues Ile263
(H6) and Leu207, Phe211 (H7); the nonpolar dCha4 side-
chain was directed toward helices 3 and 4, near Pro113,
Ser114, Arg197 and the Glu199-Arg206 salt bridge; Trp5
was placed near the hydrophobic residues Pro113, Ile116
and Val286; finally, Arg6 was proximal to Asp191, Tyr258
and Gln259, in addition to its salt-bridge with Asp282.
The final model was presented in Figure five(B) of [5].
Higginbottom et al. [5] argued that the activation of C5aR
may be prompted by the insertion of the Arg6 side-chain
at a buried position in the ligand binding pocket, past
Ile116. On the other hand, the Ar6-Asp282 interaction in
the modeled C5aR:PMX53 complex prevents the deep in-
sertion of the Arg6 guanidinium group into the pocket,
enabling the antagonist activity of PMX53. Α second
model resulted from docking attempts of PMX53 onto
C5aR with the same two constraints (Trp5-Ile116, Arg6-
Asp282), but with the disulfide bridge Cys109-Cys188
absent and the C5aR EC2 loop in an open conformation.
In the resulting model, (Figure five(C) of Higginbottom
et al.) [5], the ligand was positioned with the Phe1 side-
chain at a similar position (between helices H6 and H7),
but with the Arg6 and dCha4 interactions swapped. We
note that the covalent disulfide bridge Cys109-Cys188
should also be present in the open EC2 conformation.
As we show below, PMX53 is inserted in the second rec-
ognition region, near the modeled location of the C5a
C-terminal segment 69–74.
Ranking of the most promising C5aR:PMX53 complexes
A detailed description of our modeling procedure is pre-
sented in the Methods, and a summarizing flowchart is
shown in Figure 2. We first generated a large number of
representative conformations for the ligand and the recep-
tor by MD simulations, and grouped them into conform-
ational clusters. We then performed docking calculations
of protein and ligand conformations, without any geo-
metrical restraints. Using a filtering calculation, consisting
of conformational clustering, energy minimization and
binding free energy evaluations, we identified 35 promis-
ing binding modes covering the entire TM cavity of C5aR.
The MM-PBSA binding-free energies of these modes
ranged between −90 and −65 kcal/mol (Additional file 1:
Figure S1).
We assessed further the stabilities of all 35 structural
modes by implicit-membrane MD simulations of the
C5aR:PMX53 complex. In all cases, the initial conforma-
tions were well preserved; the average RMSD of all TM
backbone protein residues was 3.3 ± 0.2 Å relative to the
structure of Nikiforovich et al. [25] MM-PBSA analysis
of the simulation trajectories (up to 7 ns) showed that
seven structural modes (22, 6, 3, 30, 1, 4, and 10) hadsignificantly lower binding free energies. The simulations
of these models were extended to 20 ns; this length was
sufficient for convergence of the MM-PBSA association
free energies (not shown).
The free energy values (averaged over the last 17 ns
for the 20-ns trajectories, or last 4 ns for the 7-ns trajec-
tories) are plotted in Additional file 1: Figure S1 as red
diamonds. The averaged-over-simulation MM-PBSA affin-
ities are lower than the initial values of the same models.
This is mainly due to the vdW component, reflecting the
improvement of protein-ligand contacts with respect to
the initial docked structures.
Structural mode 22 has the lowest association free en-
ergy (−175 kcal/mol). Interestingly, this mode agrees with
experimental data and with features of an earlier mode
proposed by Higginbottom et al. [5] The next best modes
(6 and 3) have association free energies of −166 kcal/
mol, ~10 kcal/mol higher relative to mode 22. Mode
30 has a comparable association free energy with 6 and 3
(−165 kcal/mol), but involves an entirely different ligand
orientation. All four modes are described below.
Structural analysis of mode 22 and comparison with
experimental data
The conformation of mode 22 is displayed in Figure 3.
PMX53 is surrounded by helix 3, helix 4, the extracellular
domain EC2, helix 5, helix 6, the extracellular domain
EC3, and helix 7. The N-terminal end of the ligand points
toward the membrane interior, with the center-of-mass
(COM) of the Ac-Phe1 mainchain at a distance of ~ 5 Å
from the membrane center. The C-terminal end of the lig-
and is directed toward the membrane-water interface; the
COM of the Arg6 mainchain lies at the interface, at a dis-
tance of ca. 14 Å from the membrane center (Figure 3A).
A close-up view of the complex conformation in the
vicinity of PMX53 is shown in Figure 3 (panels B and C).
Interaction free energy components of all protein-ligand
residue pairs are displayed in Figure 4, and contact maps
are shown in Figure 5. Furthermore, a list of PMX53-
C5aR residue pairs with total intermolecular residue-pair
energies of at least 1.8 kcal/mol, as evaluated by Eq. (3), is
included in Table 1.
Ac-Phe1 is inserted into a binding pocket formed by
helices H3, H4, H5 and H6. The acetylated N-terminal
end is positioned in the interior of a triangle formed by
residues Met120 (H3), Pro214 (H4) and Trp255 (H5). A
low-occupancy hydrogen bond is formed between the Ace
CO and Tyr121 NH. The Phe side-chain participates in a
predominantly hydrophobic cluster, comprised of residues
Leu117 (H3) and the non-polar moiety of Arg206 (H5) on
one side, and Tyr121 (H3), Ala164 (H4), Leu167 (H4),
Leu209 (H5), Trp213 (H5), on the opposite side.
The Orn2 mainchain carbonyl group forms a hydrogen
bond with the NH1/2 atoms of Arg206. This hydrogen
Figure 3 The structure of binding mode 22. Panel A: The C5aR backbone is shown as a thin tan tube. The first 7 residues are omitted as in
the Nikiforovich model [25]; the Cα atom of the 8th residue is depicted as a vdW sphere. Protein segments in contact with PMX53 are indicated
in the following colors: 113–121 (H3) in green, 164–172 (H4) in orange, 188–199 (EC2) in black, 202–214 (H5) in yellow, 255–265 (H6) in purple,
278–282 (EC3) in blue, and 285–286 (H7) in pink. Panels B and C present a close-up view of the binding mode and interactions. Panel C is rotated by
180° around a vertical axis, with respect to panel B. Domains H6 and EC3 are omitted from panel B, and domains H3 and H4 are omitted from panel
C, for clarity. H4 and H5 are additionally denoted in panels B and C to assist the reader. In panels B and C, PMX53 atoms are shown in thick licorice;
selected C5aR mainchain and side-chain heavy atoms interacting with PMX53 are shown in thin licorice. All atoms are colored by atom type.
Hydrogen-bond interactions are shown as black, dashed lines.
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(100% occupancy), and is the strongest polar interaction
between the N-terminal moiety of PMX53 (residues 1–3)
and C5aR. An analogous interaction has been proposed to
form in the C5aR:C5a complex, between the Arg206 side-
chain and the C-terminal carboxylate of C5a [58]; in the
Nikiforovich model of the C5aR:C5a complex [25] the
Arg206 side-chain interacts with the C-terminal carboxyl-
ate of C5a. On the other hand, the mutation Arg206Ala
does not abrogate antagonism in linear and cyclic hexa-
peptides [5]. It is plausible that the binding mode of these
antagonists is somewhat different in the absence of the
Arg206 side-chain.
Residue Pro3 is buried between helices H5 and H6,
interacting on the H5 side with Ala203, the non-polar
moiety of Arg206 and Leu207, and on the H6 side with
residues Tyr258, Met265, and to a lesser extent Gly262.
The dCha4 carbonyl forms a medium occupancy (36%)
hydrogen bond with the Arg206 side-chain (H5). The
dCha4 side-chain ring participates in a cluster of “T-
shape” interactions with residues Trp5 (PMX53), Phe172
(H4) and His 194 (EC2). It forms additional nonpolar in-
teractions with the non-polar part of Glu199 (EC2), and
residues Val202, Ala203 (H5) and Met 265 (H6).
The Trp5 ring is located at the membrane interface,
near EC2 and helices H3 and H6. Earlier work suggestedthat this residue binds in the vicinity of Ile116 [5]. The
substitution Ile116Ala correlated with the emergence of
weak agonist activity in a PMX53 derivative with ben-
zothiazolalanine at position 5 [5], and converted a linear
peptide mimic from antagonist to agonist [58]. Based on
these results and the observation that PMX53 remains a full
antagonist of the mutant C5aR Ile116Ala, Higginbottom
et al. argued that the activation of C5aR might require
interactions between the side-chain at position 5 and res-
idues located more deeply in the binding pocket that
Ile116 [5]. In their modeling of the C5aR:PMX53 com-
plex, the proximity between Trp5 and Ile116 was intro-
duced a priori as a geometric restraint. The Trp position
in binding mode 22 is consistent with these observa-
tions and results without any restraints; Trp5 is pre-
dicted to bind in a position less buried than Ile116 (in
agreement with the PMX53 antagonist activity), and in its
vicinity (the average Ile116 CD – Trp5 O distance is 5.4 ±
0.6 Å in the MD simulation of complex 22). Its side-chain
forms a hydrogen bond with the His194 side-chain
and numerous nonpolar contacts with residues Cys188,
Gly189, Val190, Asp191, Glu199. On the other side, it in-
teracts with the side-chain of Met265. Furthermore, it
participates in a cluster of “T-shape” interactions involv-
ing residues Phe172 (H4), His 194 (EC2) and dCha4. Trp5
Cα and Cβ atoms interact with the non-polar moiety of
Figure 4 MM-GBSA interaction free-energies (kcal/mol) for all interacting protein-ligand residue pairs in binding mode 22. Panels A
and B correspond, respectively, to energies of non-polar and polar interactions, as defined in Eq. (3).
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due Ile116.
The Arg6 mainchain CO group forms a high-occupancy
(98%) hydrogen bond with the Tyr258 (H6) side-chain;
the side-chain forms two persistent salt bridges with the
Asp282 (EC3) and Asp191 (EC2) carboxylates, a frequent
(56% occupancy) hydrogen bond with Leu 278 O (EC3)
and a less frequent (18% occupancy) hydrogen bond with
Met265 S (H6). These interactions constitute the strongest
polar interaction free energy components of mode 22
(Figures 4 and 5). The Arg6-Asp282 interaction is in
agreement with earlier studies, which have shown that
Asp282 interacts with the Arg74 residue of C5a, and the
C-terminal Arg of peptide analogs [5,59,60]. Furthermore,
Arg6 makes numerous non-polar contacts with the non-
polar moieties of Tyr258, Met265, Leu278, Leu282 of
EC3, as well as nearby residues Cys287 and Val286 of H7.
The mainchain Cα atom is placed in proximity to side-
chain groups of Pro113 and Ile116 of H3.Comparison of binding modes 6, 3, 30 and 22
The next two best binding modes were 6 and 3, with cor-
responding binding free energies of −166 kcal/mol (~9-
10 kcal/mol larger relative to complex 22; see Additional
file 1: Figure S1).
Figure 6A displays a superposition of representative
conformations from the MD runs of modes 6 and 22.
The ligand mainchains are approximately at the same
distance from the membrane/water interface. They are
somewhat displaced relative to each other in a direction
parallel to the interface (xy plane), and are rotated by ca.
60° around the perpendicular axis Oz, and to a smaller ex-
tent around axes vertical to planes xz and yz. The RMSD
between the ligand conformations with the lowest binding
free energies for modes 6 and 22 is ~ 4.5 Å (ligand atoms
N, Cα, and C).
In the simulations of binding mode 22, PMX53 forms
two stable intermolecular salt bridges (Arg6-Asp282 and
Arg6-Asp191). In the simulations of mode 6, Arg6 makes
Figure 5 Probability (%) maps of C5aR:PMX53 intermolecular contacts and hydrogen bonds, computed from the MD simulation
trajectory of binding mode 22. Panels A, B, C and D, show, respectively, protein side-chain – ligand side-chain, protein mainchain – ligand
mainchain, protein side-chain – ligand mainchain, and protein mainchain – ligand side-chain contacts. A contact was considered present in a
trajectory snapshot, if the distance betweeen the geometric center of the corresponding moieties was smaller than 6.5 Å. Panel E displays a
probability map (%) of C5aR:PMX53 hydrogen bonds. A hydrogen bond among two heavy atoms was considered present if the donor-acceptor
distance was smaller than 3.5 Å and the D-H – A angle was larger than 90°.
Table 1 Residue pairs forming strong intermolecular
interactions in binding mode 22
PMX53 C5aR1
Ac-Phe1 Tyr121, Met120, Arg206, Leu117, Leu209, Trp255, Gly210,
Pro214, Ala164, Trp213, Leu167
Orn2 Arg206, Leu117, Tyr258, Ile116, Met120, Pro113
Pro3 Arg206, Tyr258, Ala203, Leu207, Met265
dCha4 Arg206, Phe172, Glu199, Met265, Ala203, Val202, His194
Trp5 Val190, His194, Gly189, Cys188, Asp191, Glu199, Pro113,
Met265, Phe172
Arg6 Asp282, Asp191, Met265, Leu278, Leu281, Tyr258, Ile116
1Intermolecular energies were computed with Eq. (3) and were averaged over
the simulation trajectory; only pairs with total energies of at least 1.5 kcal/mol
are tabulated. In each line, the C5aR residues are listed in descending order of
total interaction energy with the corresponding PMX53 residue. Italics denote
C5aR residues engaged in strong polar interactions.
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second half of the simulation (not shown). Numerous new
interactions are observed: The Trp5 side-chain forms inter-
actions with the side-chains of residues Cys109, Leu112,
Pro113. PMX53 segment 1–3 interacts with helix H6 in
mode 6, and helices H3 and H5 in mode 22.
Figure 6B displays a superposition of representative
PMX53 conformations from binding modes 3 and 22;
the RMSD between the conformations with the lowest bind-
ing free energies is ~ 4.4 Å (ligand atoms N, Cα, and C).
The peptide binds at a similar distance from the mem-
brane interface as in modes 6 and 22, and at a similar
orientation (with its N-terminal end pointing toward the
membrane center). Compared to mode 22, it is rotated
Figure 6 Comparison of PMX53 structures from the MD simulations of modes 6 (gray; panel A), 3 (gray; panel B), and 30 (gray; panel
C) superposed against the lowest binding free energy conformation of complex 22 (red; all panels). The conformations shown have the
lowest binding free energy among all snapshots of the corresponding trajectory (in the MM-PBSA approximation). The structures are aligned
using the mainchain transmembrane atoms of C5aR. All ligand hydrogen atoms are omitted for clarity. The C5aR segments interacting with the
ligand are shown in different colors, in tube representation; the coloring scheme is the same as in Figure 3.
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chains point toward opposite directions and the moiety
1–5 interacts mainly with helices H5 and H6. Arg6 forms
polar and non-polar interactions with domains E23, H4
and EC2, and a stable salt bridge with Glu199. Interest-
ingly, Higginbottom et al. have argued that Glu199 might
form an interaction with the terminal Arg side-chain of
C5 and peptide mimics, and introduced a Glu 199 – Arg6
salt bridge as a restraint in a C5aR – PMX53 docking
study described in Ref. [5] (Figure five(C) of that work)
[5]. In our mode 3 this interaction is predicted without
any guiding restraint. We note that the extracellular loop
EC2 of that Higginbottom model had a more open con-
formation and the Cys109 – Cys188 disulfide bridge was
absent; however, the disulfide bridge is a covalent figure
and should still be present in the open-loop conformation.
Figure 6C displays a superposition of representative
PMX53 conformations from binding modes 30 and 22.
Unlike modes 22, 3 and 6, here the N-terminal end of
the ligand is oriented toward the membrane interface
and the N-terminal Ac group is positioned near the EC2
loop. In this orientation, the ligand N-terminal Ac group
is more amenable to substitutions, in agreement with
the experimental observation that the replacement of
the Ac group by a range of groups with variable size,
hydrophobicity and hydrophilicity does not affect the af-
finity or antagonist activity of PMX53 against C5aR [61].
Despite the change in orientation, the ligand makes the
same two key intermolecular electrostatic interactions
observed in mode 22 (see Additional file 1: Figure S2):
The Arg6 side-chain forms persistent salt-bridges with
Asp282 and Asp191 throughout the simulation, as was
observed in mode 22. The Orn2 CO group makes a stable
hydrogen bond with the Arg206 side-chain in the segment
9.5 ns – 20 ns. The binding free energy of mode 30
is −155 kcal/mol in the first 9.5 ns and −165 kcal/mol in
the last 7.5 ns of the simulation. Interestingly, in mode 30the Trp5 side-chain is positioned between the side-chains
of Ile116 and Val286; this pair has been suggested to form
an activation switch for C5aR [58]. The average distances
Trp5 CH2 - Ile116 CG2 and Trp5 CH2 - Val286 CG are,
respectively, 4.6 ± 1.2 Å, and 5.0 ± 0.6 Å.
Comparison of binding mode 22 and the C5a:C5aR complex
(Nikiforovich model)
A detailed comparison of the promising binding modes for
the C5aR:PMX53 complex, predicted in this work, and the
Nikiforovich model for the C5aR:C5a complex [25] can
help interpret the antagonist activity of PMX53. Figure 7
displays the binding conformations of C5a and PMX53 li-
gands, obtained by alignment of the intra-membrane C5aR
mainchain heavy atoms in the C5aR:C5a complex (Nikiforo-
vich model) and C5aR:PMX53 complex (mode 22) with the
program SuperPose [62]. Additional file 1: Figure S3A-D
display maps of side-chain and mainchain contacts in
the C5a:C5aR Nikiforovich model; [25] intermolecular
hydrogen bonds in the C5a:C5aR complex are presented
in Additional file 1: Figure S3E.
According to the superposition presented in Figure 7,
PMX53 blocks the entry of the C5a C-terminal into the
transmembrane domain of C5aR, by occupying the pos-
ition in which the C-terminal domain of C5a binds and
promotes signaling. PMX53 does not directly act as a
mimetic of the C5a C-terminal, as PMX53 is cyclic and
the C-terminal domain of C5a is linear. Upon superpos-
ition of the PMX53 and C5a in complex with C5aR, the
N-terminal end of PMX53 coincides with the C-terminal
end of C5a, while the 71–73 C-terminal domain of C5a
is placed between the PMX53 3–5 backbone moiety on
one site and the Orn2 side-chain moiety on the other
site. Also, the backbone of C5a residues Asp369 and
Met370 structurally coincide, upon superposition, with
the side-chain of PMX53 residue Trp5. The C5aR resi-
due Asp191 makes a salt bridge with PMX53 residue
Figure 7 The C5aR:PMX53 complex (conformation of lowest
binding free energy in the simulation of binding mode 22) is
superposed against the Nikiforovich model [25] for the C5aR:
C5a complex. The C5aR mainchain (mode 22) is indicated by a thin
tan tube, and the Cα atom of the first N-terminal end residue of the
simulation system (8th residue of C5aR) by a vdW sphere. Interacting
protein domains are colored in different colors; the coloring scheme
is as in Figure 3. C5a is displayed as a red tube and the Cα atom of the
1st residue is indicated by a vdW sphere. PMX53 is shown in licorice,
colored by atom type. Hydrogen atoms are omitted for clarity.
Tamamis et al. BMC Biophysics 2014, 7:5 Page 13 of 16
http://www.biomedcentral.com/2046-1682/7/5Arg6 in mode 22, and with C5a residue Lys68 in the
C5aR:C5a complex. Furthermore, the first four PMX53 res-
idues interact strongly with H5 residues Ala203, Arg206,
Leu207, Leu209; these interactions could compete with
interactions within the C5a 69–74 residue moiety, and
particularly with the salt bridge between Arg206 and the
C-terminal carboxyl group of Arg74. Last but not least,
H6 residues Gly262 and Met265 interact with C5a seg-
ment 67–70 and Arg74 in the Nikiforovich model; these
interactions may also be blocked by interactions of C5aR
with Orn2, Pro3, dCha4 and Trp5 of PMX53.
Conclusion
In the present work we construct structural models for
the complex of membrane-embedded C5aR and its an-
tagonist peptide PMX53 via a computational framework
that combines conformational sampling for both recep-
tor and ligand, docking and filtering of conformations by
structural and energetic criteria. A large body of experi-
mental results suggests that the C5aR binding site of the
antagonist cyclic hexapeptide PMX53 is at or near the
TM binding site of the C5aR agonist peptide C5a [5].
The key PMX53 residue Trp5, an important determinant
of antagonism, is likely to be positioned near Ile116, a
residue implicated in interactions with the PMX family
of peptides and possibly the activation of C5aR [58]. Fur-
thermore, Arg6 has been shown to interact with Asp282[5]. The most promising binding mode (22) and several
other modes of low binding free energy reproduce both
interactions. An additional interaction is observed in
several high-affinity modes, between the mainchain CO
group of Orn2 and the Arg206 side-chain. An analogous
interaction has been proposed to form in the C5aR:C5a
complex, between the Arg206 side-chain and the C-
terminal carboxylate of C5a [58] and is present in the
Nikiforovich model of the C5aR:C5a complex [25].
Notably, the aforementioned interactions are predicted
without imposing any a priori geometric constraints in
the initial conformations of the complexes. This success-
ful outcome lies in the use of a multi-step computational
framework, which included the generation of representa-
tive receptor and ligand conformations by long MD sim-
ulations with high quality implicit-membrane models,
the docking of a large combination of receptor and ligand
conformations, the comprehensive filtering of several hun-
dred thousand conformations for the complex by struc-
tural and free energy criteria, and the re-evaluation of the
most promising binding modes by additional MD simula-
tions and binding free energy calculations. 2. Membrane
effects were introduced by high-quality implicit-membrane
models [29-31], which enabled both the rapid generation
of representative structures and the estimation of their
binding affinities. Therefore, the computational framework
used here is capable of addressing the challenges in gener-
ating reliable structural models for GPCR protein-ligand
complexes of unknown structure. While, the MM-PBSA
and MM-GBSA methods yield large binding free energy
values [53,54,63], their use in the specific computational
protocol of this study proved useful, with regard to identi-
fying the lowest binding free energy, and thus, the most
promising PMX53:C5aR binding mode. The large affinity
free energies are partly attributed to the omission of the
protein, ligand and complex configuration entropy contri-
butions to binding; due to energy-entropy compensation,
when these terms are included in the calculation, they are
expected to yield significantly smaller total free energies
[64]. These entropic terms are associated with large uncer-
tainties and are expected to cancel out to a large extent in
the relative affinities of different binding modes. Therefore,
their omission is not expected to be important at the level
of accuracy of the present calculation, which identifies
most promising binding modes. In a similar fashion, the
membrane MM-PBSA and/or MM-GBSA approximations
were used to identify the most promising binding modes
of a dual tropic HIV-1 gp120 V3 loop in complex with
CXCR4 and CCR5, CXCL12 (SDF-1α) in complex with
CXCR4 and CCL5 (RANTES) in complex with CCR5; the
computationally derived structures were in exceptional
agreement with experimental findings [65-68].
The structure of membrane-embedded C5aR:PMX53
complex and its dynamic features, presented here, will
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peptide, peptidomimetic, and organic compound antago-
nists of C5aR for targeting of complement-mediated auto-
immune and inflammatory diseases. Such antagonists may
have superior ADMET (absorption, distribution, metab-
olism, excretion, and toxicity) properties compared to
PMX53 and therefore be more amenable to clinical devel-
opment. Also, the methodology developed for the gener-
ation of the structure of membrane-embedded C5aR:
PMX53 prepares the grounds for the generation of similar
models for the homologous receptors C3aR and C5L2
with their respective endogenous ligands, as well as ago-
nists and antagonists. C5aR, C3aR, and C5L2 have com-
mon as well as distinct structural features and biological
functions. Comparative studies at atomic resolution will
shed light on the underlying structural, physicochemical,
and dynamic properties that mediate the similarity and
variability in their structures, dynamics, binding proper-
ties, and biological functions.
Although the database of solved GPCR structures is
slowly but steadily increasing, and there are more struc-
tural templates available today for computational modeling
than previously, still there is no structural information for
the vast majority of GPCRs; and structural information on
GPCR-ligand binding at atomic resolution is rare. The
computational framework presented here can be of wide
use for the development of GPCR-ligand structural models
in membrane environments. Such models will be useful in
providing the structural basis for mechanistic studies of
the interactions between GPCRs and ligands, and their ef-
fects in intra-membrane and intra-cellular dynamics that
drive the selection of intra-cellular activation pathways. In
addition, such models will be useful in knowledge-based
biopharmaceutical discovery.
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